/
Oncology
Advanced Solid Tumors
312
Pipeline Programs↗
294
Active Trials↗
251
Companies Involved↗
Advanced Solid Tumors is a highly competitive landscape with 312 programs across 251 companies. The most active players are AbbVie, Qilu Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical16
Phase 1160
Phase 2136
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
239 of 287 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 287 classified programs, each share of the total. Modality classified for 100% of 312 pipeline programs.
Analysis
Trial Status
870
clinical trials
Completed328 · 38%
Recruiting196 · 23%
Terminated140 · 16%
Unknown status90 · 10%
Not yet recruiting52 · 6%
Active, not recruiting45 · 5%
Other19 · 2%
Clinical Trials
Trial Activity
870 trials
Page 1 of 58
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)